Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical University of Graz | OTHER |
Not provided
Not provided
Not provided
Not provided
Postoperative cardiovascular complications are common after noncardiac surgery. The association between perioperative inflammation and the occurrence of cardiovascular complications after surgery is still unknown. Therefore, we will evaluate as our primary aim the association between patients with increased postoperative inflammation, assessed with C-reactive protein measurements, and the occurrence of major cardiovascular complications after noncardiac surgery. We will further evaluate the influence of perioperative inflammation on the occurrence of postoperative acute kidney injury. We will also evaluate the association between inflammation and the influence on Days-At-Home within 30 days. Furthermore, we will evaluate the association between increased inflammatory biomarkers and postoperative N-terminal pro brain natriuretic peptide (NT-proBNP) concentration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients at least 45 years at-risk for cardiovascular complications |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Laboratory measurements | Diagnostic Test | Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composite of cardiovascular complications | The primary aim of the study is to investigate the influence of the maximum C-reactive protein value (over the first 3 days after surgery) on the incidence of major cardiovascular complications within 30 days after surgery. The composite binary endpoint is defined as myocardial infarction, myocardial injury after noncardiac surgery, new onset of atrial fibrillation, stroke or death. | within 30 days after surgery and one year after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| C-reactive protein | Secondary goals of the study are to investigate the influence of the C-reactive protein on day 5 on the incidence of cardiovascular complications within 30 days after surgery (combined binary endpoint). | within 30 days after surgery |
| Acute Kidney Injury - C-reactive proteint |
| Measure | Description | Time Frame |
|---|---|---|
| Atrial fibrillation (AF) evaluation | To evaluate the incidence of asymptomatic atrial fibrillation (AF) and symptomatic AF. Asymptomatic AF will be defined as irregular pulse without any clinical symptoms. Symptomatic AF will be defined as irregular pulse with one of the symptoms including racing heart, fluttering or palpitations; fatigue, shortness of breath; and lightheadedness. | within 5 days after surgery |
All patients need to meet all of the following criteria for inclusion (1-4):
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients at least 45 years and at-risk to develop postoperative cardiovascular complications undergoing noncardiac surgery.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christian Reiterer, MD | Contact | 004340400 | 20760 | christian.reiterer@meduniwien.ac.at |
| Barbara Kabon, MD | Contact | 004340400 | 41020 | barbara.kabon@meduniwien.ac.at |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of Vienna | Recruiting | Vienna | 1090 | Austria |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24864079 | Background | Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014 Jul 14;35(27):1782-91. doi: 10.1093/eurheartj/ehu203. Epub 2014 May 26. | |
| 24026779 | Background | Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jorgensen T, Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014 Mar;35(9):578-89. doi: 10.1093/eurheartj/eht367. Epub 2013 Sep 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D017202 | Myocardial Ischemia |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
We will evaluate the influence C-reactive protein on the occurrence of postoperative acute kidney injury. |
| within 5 days after surgery |
| Acute Kidney Injury - Interleukin 6 | We will evaluate the influence of Interleukin 6 on the occurrence of postoperative acute kidney injury. | within 5 days after surgery |
| Acute Kidney Injury - Procalcitonin | We will evaluate the influence of Procalcitonin on the occurrence of postoperative acute kidney injury. | within 5 days after surgery |
| Acute Kidney Injury - Copeptin | We will evaluate the influence of Copeptin on the occurrence of postoperative acute kidney injury. | within 5 days after surgery |
| Days at home within 30 days (DAH 30) | We will evaluate the correlation between perioperative inflammation (C-reactive protein, Interleukin 6, Procalcitonin, Copeptin) and the number of days patient spend at home after surgery within 30 days (DAH30). Outcomes measure: Hospital discharge data will be used to calculate hospital length of stay. DAH30 will be calculated using mortality and hospitalization data from the date of the index surgery (day 0). For example, if a patient will die on day 2 after surgery, they were assigned 0 DAH30. If a patient will be discharged from hospital at day 6 after surgery but will be readmitted for 4 days before the second hospital discharge, we will assign 20 DAH30. If a patient will die within 30 days after surgery, irrespective of whether they will spend time at home, DAH30 will be scored as 0. | within 30 days after surgery |
| NT-proBNP | We will evaluate the correlation of each of the following inflammatory parameters including C-reactive protein, Interleukin 6, Procalcitonin, Copeptin on postoperative NT-proBNP concentration. NT-proBNP will be measured before surgery, and on the first, second and third postoperative day. | within 5 days after surgery |
| Interleukin 6 | We investigate the influence of the Interleukin 6 ,measured within the first five days after surgery, on the incidence of cardiovascular complications within 30 days after surgery (combined binary endpoint). | within 30 days after surgery |
| Copeptin | We investigate the influence of the copeptin ,measured within the first five days after surgery, on the incidence of cardiovascular complications within 30 days after surgery (combined binary endpoint). | within 30 days after surgery |
| Procalcitonin | We investigate the influence of the procalcitonin ,measured within the first five days after surgery, on the incidence of cardiovascular complications within 30 days after surgery (combined binary endpoint). | within 30 days after surgery |
| SARS-Cov-2 - Inflammation | We will evaluate the effect of having a perioperative or previous infection with Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) on postoperative inflammatory parameters including C-reactive protein, Copeptin, Interleukin 6 and Procalcitonin. | within first 5 days after surgery |
| SARS-Cov-2 - Cardiovascular Complications | We will evaluate the effect of having a perioperative or previous infection with SARS-CoV-2 on the incidence of our composite outcome including myocardial myocardial infarction, myocardial njury after noncardiac surgery, new onset of atrial fibrillation, stroke or death. We will evaluate the outcome one year after surgery via a telephone interview. | One year after surgery |
| SARS-Cov-2 One Year Follow-Up | We will evaluate the effect of a perioprative or previous SARS-Cov-2 infection on the neurocognitive function one year after surgery. Therefore, we will perform the telphone Montreal Cognitive Assessment (MoCA) before surgery and one year after surgery. | One year after surgery |
| 28444280 | Background | Writing Committee for the VISION Study Investigators; Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P, Faruqui A, Heels-Ansdell D, Lamy A, Whitlock R, LeManach Y, Roshanov PS, McGillion M, Kavsak P, McQueen MJ, Thabane L, Rodseth RN, Buse GAL, Bhandari M, Garutti I, Jacka MJ, Schunemann HJ, Cortes OL, Coriat P, Dvirnik N, Botto F, Pettit S, Jaffe AS, Guyatt GH. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA. 2017 Apr 25;317(16):1642-1651. doi: 10.1001/jama.2017.4360. |
| 29146124 | Background | Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3. Epub 2017 Nov 13. |
| 37474184 | Derived | Pichler A, Kurz A, Eichlseder M, Graf A, Eichinger M, Taschner A, Kabon B, Fleischmann E, Reiterer C; INSIGHT study group. PerIoperative iNflammatory reSponse assessment In hiGH-risk patienTs undergoing non-cardiac surgery (INSIGHT): study protocol of a prospective non-interventional observational study. BMJ Open. 2023 Jul 19;13(7):e065469. doi: 10.1136/bmjopen-2022-065469. |
| D014652 | Vascular Diseases |